Protein subunit vaccines

class of vaccines against human papillomavirus

vaccine that is used to prevent malaria

single protein molecule that assembles with other protein molecules to form a protein complex

Gardasil is an HPV vaccine for use in the prevention of certain strains of human papillomavirus (HPV). It was developed by Merck & Co. High-risk human papilloma virus (hr-HPV) genital infection is the most common sexually transmitted infection among women. The HPV strains that Gardasil protects against are sexually transmitted, specifically HPV types 6, 11, 16 and 18. HPV types 16 and 18 cause an estimated 70% of cervical cancers, and are responsible for most HPV-induced anal, vulvar, vaginal, and penile cancer cases. HPV types 6 and 11 cause an estimated 90% of genital warts cases. HPV type 1

vaccine candidate against COVID-19

COVID-19 vaccine made by Medigen

Cervarix is a vaccine against certain types of cancer-causing human papillomavirus (HPV).

recombinant protein subunit vaccine against COVID-19

EuCorVac-19 is a COVID-19 vaccine candidate developed by EuBiologics Co.

COVAX-19 (or SpikoGen) is a recombinant protein-based COVID-19 vaccine developed by South Australian-based biotech company Vaxine, in collaboration with CinnaGen, a private company with operations in West Asia. It is under clinical trial in collaboration with the Iranian company CinnaGen.

Iranian vaccine against COVID-19

Skycovione is a COVID-19 vaccine candidate developed by SK Bioscience and the Institute for Protein Design of the University of Washington, It is South Korea's first homegrown COVID-19 vaccine and utilizes GSK's AS03 adjuvant technology. ==Trials and regulation== The phase III clinical trial involves 4,037 participants. In April 2022, results of the phase III trial confirmed the vaccine to be safe and effective. It elicited approximately three times more antibodies than the Oxford–AstraZeneca COVID-19 vaccine. The South Korean Government has ordered 10 million doses for domestic use.

SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. Positive results of Phase I trials for the vaccine were published in The Lancet and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021. In September 2021, SCB-2019 announced Phase III results showing 67% efficacy against all cases of COVID-19 and 79% efficacy against all cases of the Delta variant. Additionally, the vaccine was 84% effective against moderate cases and 100% effective against hospitalization.

V-01 is a protein subunit COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical Group Inc. __TOC__ == Preclinical studies ==

vaccine candidate against COVID-19

vaccine candidate against COVID-19

vaccine candidate against COVID-19

experimental vaccine targeting SARS-CoV-2